TY - JOUR
T1 - Inflammatory bowel disease
AU - Hansen, Richard
AU - Cameron, Fiona Louise
AU - Hold, Georgina Louise
AU - El-Omar, Emad Munir
AU - Russell, Richard Kay
N1 - Funding Information:
The authors wish to acknowledge funding from the Broad Foundation , USA, and the Chief Scientist Office , Scotland. RH is funded by a fellowship from the Chief Scientist Office in Scotland.
PY - 2010/10
Y1 - 2010/10
N2 - Inflammatory bowel disease (IBD) describes a heterogeneous group of chronic inflammatory diseases of the gastrointestinal tract, of which Crohn's disease and ulcerative colitis are the most common diagnoses. About a quarter of IBD presents in childhood, and the phenotype seen involves a wider disease distribution in both Crohn's and ulcerative colitis than seen in adult-onset disease. The incidence of IBD appears to be rising and although we understand more about the genetic, immunological and environmental contributors to aetiology, we do not yet fully understand this rise. In paediatric practice, IBD and in particular Crohn's disease, often results in impaired weight gain, poor linear growth and delayed puberty. Multiple treatment modalities exist for IBD from longstanding treatments such as steroids and immunosuppressants to modern, targeted therapies such as infliximab. This review discusses the current state of the art of clinical practice in relation to paediatric IBD.
AB - Inflammatory bowel disease (IBD) describes a heterogeneous group of chronic inflammatory diseases of the gastrointestinal tract, of which Crohn's disease and ulcerative colitis are the most common diagnoses. About a quarter of IBD presents in childhood, and the phenotype seen involves a wider disease distribution in both Crohn's and ulcerative colitis than seen in adult-onset disease. The incidence of IBD appears to be rising and although we understand more about the genetic, immunological and environmental contributors to aetiology, we do not yet fully understand this rise. In paediatric practice, IBD and in particular Crohn's disease, often results in impaired weight gain, poor linear growth and delayed puberty. Multiple treatment modalities exist for IBD from longstanding treatments such as steroids and immunosuppressants to modern, targeted therapies such as infliximab. This review discusses the current state of the art of clinical practice in relation to paediatric IBD.
KW - Children
KW - Crohn's disease
KW - Inflammatory bowel disease
KW - Treatment
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=77957277541&partnerID=8YFLogxK
U2 - 10.1016/j.paed.2010.04.005
DO - 10.1016/j.paed.2010.04.005
M3 - Review article
AN - SCOPUS:77957277541
SN - 1751-7222
VL - 20
SP - 473
EP - 478
JO - Paediatrics and Child Health
JF - Paediatrics and Child Health
IS - 10
ER -